Compare Citius Pharmaceuticals Inc (CTXR) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Las Vegas Sands Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Las Vegas Sands Corp. trades at $44.72 (market cap $29.67B). The key difference: Las Vegas Sands Corp. is far larger — about 2026.6× Citius Pharmaceuticals Inc's market cap, and Las Vegas Sands Corp. pays a 2.46% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | LVS | |
|---|---|---|
Market Cap | $14.64M | $29.67B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $69.49 |
52-Week Low | $0.53 | $44.78 |
Enterprise Value | $10.86M | $42.07B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
LVS trades at $45.90, down 1.69% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q1 2026 revenue of $3.59 billion, up 25.3% year-over-year, and EPS of $0.91, beating estimates. Analyst consensus is strongly bullish with a $65.56 price target, though technical indicators show selling pressure near key support at $45.
LVS presents a compelling value opportunity with a P/E of 16.94 and consistent earnings beats, but faces headwinds from high debt levels and bearish technical momentum. Upside potential exists if the stock holds support and executes on growth, while downside risk persists if macroeconomic or regulatory pressures intensify.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
